Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270431 | 1.00 | TRPA1 (0.36) | TRPA1TRPM8MEN1ALDH1A1KMT2A | |
| SCHEMBL10162372 | 1.00 | TRPA1 (0.36) | TRPA1TRPM8MEN1ALDH1A1KMT2A | |
| SCHEMBL12696839 | 0.92 | TRPA1 (0.32) | TRPA1TRPM8 | |
| SCHEMBL9613629 | 0.92 | TRPA1 (0.32) | TRPA1TRPM8 | |
| SCHEMBL12002414 | 0.92 | TRPA1 (0.32) | TRPA1TRPM8 | |
| SCHEMBL127724 | 0.87 | — | — | |
| SCHEMBL240851 | 0.87 | ALDH1A1 (0.36) | ALDH1A1ALOX5 | |
| SCHEMBL5444346 | 0.87 | — | — | |
| SCHEMBL342675 | 0.87 | — | — | |
| SCHEMBL8183333 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-17 | — | — | US | disclosed |
| US-9682978-B2 | 2,6,7 substituted purines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150368247-A1 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-24 | — | — | US | disclosed |
| EP-2953470-A1 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014123882-A1 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368247-A1 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS | DDX21, NSUN2, DHX29 | TRPA1 4037/4885TRPM8 3532/4885MEN1 2788/4885 |
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE4D | TRPA1 4136/4885TRPM8 4164/4885MEN1 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.